Business Context and Reporting Period
Company: DanDrit Biotech USA, Inc. (Note: Request metadata referenced "Lunai Bioworks Inc.", but the filing text identifies the registrant as DanDrit Biotech USA, Inc.)
Filing Type: Form 8-K (Current Report)
Reporting Date: November 14, 2014 (Event Date: November 13, 2014)
Event: Final closing of a registered direct placement of common stock.
Key Financial Metrics
- Final Closing Proceeds: $292,500 gross proceeds from the sale of 58,500 shares at $5.00 per share.
- Total Offering Proceeds: $5,466,450 gross proceeds from the aggregate sale of 1,093,290 shares.
- Transaction Costs: $3,500 in cash commissions paid to the placement agent (7% of Final Closing proceeds) and $25,000 in cash for counsel fees (portion of 1% expense reimbursement).
- Use of Proceeds: To be utilized in accordance with the "Use of Proceeds" section of the Registration Statement.
- Other Metrics: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports the completion of the "Offering," which was a "best efforts" public sale of up to 2,400,000 shares. Following the Final Closing on November 13, 2014, the Offering is now closed. The company successfully sold approximately 45.6% of the maximum authorized shares (1,093,290 shares) under the Registration Statement.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use the gross proceeds as described in the Registration Statement filed on February 14, 2014.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard completion of the offering. The description of the Placement Agency Agreement is qualified by reference to the full text filed as an exhibit.
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("Lunai Bioworks Inc.") and the actual registrant name in the filing ("DanDrit Biotech USA, Inc.").
- Review the "Use of Proceeds" section in the Registration Statement (File No. 333-193965) to understand capital allocation plans.
- Examine the full Placement Agency Agreement (Exhibit 1.1) for additional terms regarding the 7% commission and expense reimbursements.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.